SCHEMBL6863831

SCHEMBL6863831

O=C(O)c1ccc(NC(=O)c2cc(Cl)ccc2NS(=O)(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.63
TP53 P04637 2/20 0.63
LMNA P02545 2/20 0.63
HTT P42858 2/20 0.63
MAPT P10636 1/20 0.63
SLC10A6 Q3KNW5 2/20 0.62
SLC10A2 Q12908 1/20 0.62
SLC10A1 Q14973 1/20 0.62
GPR27 Q9NS67 4/20 0.57
CPT2 P23786 1/20 0.54
CPT1A P50416 1/20 0.54
CPT1B Q92523 1/20 0.54
PTPN1 P18031 1/20 0.54
AVPR2 P30518 1/20 0.54
MEN1 O00255 2/20 0.53
P2RX1 P51575 1/20 0.53
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6862206 0.94 SLC10A6 (0.65) KMT2ATP53LMNAHTTMAPT
SCHEMBL6862400 0.93 SLC10A6 (0.71) KMT2ATP53SLC10A6SLC10A2SLC10A1
SCHEMBL6860624 0.90 SLC10A6 (0.64) KMT2ATP53LMNAHTTSLC10A6
SCHEMBL1138705 0.90 SLC10A6 (0.63) KMT2ATP53LMNAHTTSLC10A6
SCHEMBL6860636 0.89 LMNA (0.64) KMT2ATP53LMNAHTTMAPT
SCHEMBL6862376 0.89 SLC10A6 (0.76) KMT2ATP53SLC10A6SLC10A2SLC10A1
SCHEMBL6861353 0.89 CCR9 (0.62) SLC10A6SLC10A2SLC10A1GPR27CPT2
SCHEMBL6856054 0.87 GPR27 (0.57) KMT2ATP53SLC10A6SLC10A2SLC10A1
SCHEMBL5126827 0.86 KMT2A (0.61) KMT2ATP53LMNAHTTMAPT
SCHEMBL6860504 0.86 SLC10A6 (0.59) KMT2ALMNAHTTMAPTSLC10A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US claimed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP claimed
CN-1213019-C Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2005-08-03 CN disclosed
US-6790866-B2 SUCH AS 4-(2-PHENYLSULFONYLAMINO-5-CHLOROBENZOYLAMINO)BENZOIC ACID FOR USE AS PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; FOR INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, AND/OR FOR INCREASE OF VESICAL CAPACITY ONO PHARMACEUTICAL CO., LTD. (JP) 2004-09-14 US disclosed
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity OHUCHIDA SHUICHI (JP) 2003-03-27 US disclosed
US-6448290-B1 PROSTAGLANDIN E2 ANTAGONIST OR AGONIST; INHIBITION OF UTERINE CONTRACTION, ANALGESICS, ANTIDIARRHEALS, SLEEP INDUCERS, INCREASING VESICAL CAPACITY, CATHARTIC, SUPPRESSION OF GASTRIC ACID SECRETION, ANTIHYPERTENSIVE, DIURETIC AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-09-10 US disclosed
CN-1247529-A Sulfonamide and carboxamide derivatives and drugs containing same as active ingredient ONO PHARMACEUTICAL CO (JP) 2000-03-15 CN disclosed
EP-0947500-A1 SULFONAMIDE AND CARBOXAMIDE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 1999-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060460-A1 Such as 4-(2-phenylsulfonylamino-5-chlorobenzoylamino)benzoic acid for use as prostaglandin E2 antagonist or agonist; for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, and/or for increase of vesical capacity CNR1, HCAR1, HCAR2 KMT2A 1316/4885TP53 4843/4885LMNA 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.